GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced its development program for PerQseal ® ...
Ra Medical Systems Inc. launched a simple device that holds sutures more securely in place for closure of percutaneous wound sites during cardiac electrophysiology, structural heart and vascular ...
The explosion of innovation in valve replacement and repair markets is opening a huge opportunity for percutaneous vessel closure devices. Edward Lifesciences’s FDA nod for the Evoque Transcatheter ...
Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication! Receive the the latest news, research, and presentations from major meetings ...
(RTTNews) - Shares of Catheter Precision Inc. (VTAK) are up over 65% at $4.36, following an encouraging regulatory news related to its LockeT wound closure device. LockeT is a suture retention device ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results